For Healthcare Private Equity
IC-grade clinical, regulatory, and manufacturing diligence on each target — from an automated Quick Screen for triage to Diligence and M&A Reports reviewed by a physician and a biomedical engineer. Firms screening at volume can license Vantage through Enterprise, priced to the portfolio. Factual claims are cited to their sources.
Screening a Pipeline
Run a Quick Screen on each company in your pipeline: six independent signals per company, each linked to its source records, with no composite score and no ranking verdict.
Competitive Advantage
Faster and less expensive than a traditional analyst engagement, with sources you can check.
What We Find
Six of the areas a full report reads.
Diligence domains per full report
Companies in our substrate
Public data sources
Review on full reports
Will physicians change workflow? The report reads the adoption questions a financial review is not built to ask.
Manufacturing, quality and supplier questions, read from recalls, FDA records and the materials you provide.
Predicate and pathway questions, read against FDA's record. A misjudged pathway can add months and material cost.
Devices with unclear payer pathways can stall after FDA authorization. The report reads coding, coverage and payment records.
Comparable companies drawn from a substrate of 3,900+ biomedical companies and 4.7 million public records.
Reliance on a single payer is a concentration risk. The report shows where coverage decisions sit in the public record.
Pricing
Per-deal reports are the entry point. Firms screening at volume can license Vantage through Enterprise, with a scoped annual report allowance priced to the portfolio.
Typical PE workflow: Start with a Quick Screen across the pipeline, commission a Diligence Report on finalists, and use the M&A Report for platform or bolt-on acquisitions. Firms screening at volume can license Vantage through Enterprise, priced to the portfolio. Contact us for a scoped proposal.
Enterprise: a scoped annual Quick Screen and Diligence Report allowance, priced to your portfolio. Per deal: Quick Screen $5,000 · Diligence Report $20,000 · M&A Report $25,000.
A single missed clinical, manufacturing or reimbursement question can cost far more than the diligence that would have surfaced it.
Deal Integration
From deal sourcing through the investment committee
Quick Screens across inbound deals
Rapid triage on target profile and strategic fit
Diligence Report on finalists
Diligence findings in front of the IC
M&A Report on platform or bolt-on targets
How we'd diligence a platform
Each card is a public retrospective, not a private case. The point is to show the framework: what the public record showed, and the questions it raised.
Recalls of polyethylene implant components over a packaging defect (2021–22), then Chapter 11 in 2024. Walks the manufacturing-control and complaint-trend questions visible in the public record.
Read the retrospective →An October 2021 FDA warning letter, after Owlet’s July 2021 SPAC listing, said the Smart Sock was being marketed as an uncleared medical device, and Owlet stopped selling it in the US. Walks the classification questions visible in the public record.
Read the retrospective →An early FDA-authorized prescription digital therapeutic, a 2021 SPAC listing and a 2023 bankruptcy. Traces the payer-coverage and prescribing-economics questions visible in the public record.
Read the retrospective →These are public retrospectives, not client engagements.
A scoped annual allowance of Quick Screens and Diligence Reports across your platform and add-ons, priced to your portfolio. Factual claims are cited to their sources, drawn from our proprietary multi-source substrate.
Talk to Arvind Ravinutala, MD →Enter per deal with a Quick Screen or Diligence Report, or talk to Arvind Ravinutala, MD, about an Enterprise license priced to your portfolio.
10 regulatory, clinical, and commercial red flags to check before a healthcare deal — written by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the GuideNo email required. No paywall.